
TNF alpha Rabbit pAb

Catalog Number: bs-0078R

Target Protein: TNF alpha

Concentration: 1mg/ml

Form: Liquid

Host: Rabbit

Clonality: Polyclonal

Isotype: IgG

Applications: WB (1:500-2000), Flow-Cyt (1ug/Test)

Reactivity: Human, Mouse (predicted:Pig, Dog, Horse)

Predicted MW: 17/26 kDa

Detected MW: 17.5/26 kD kDa

Entrez Gene: 7124

Swiss Prot: P01375

Source: KLH conjugated synthetic peptide derived from human TNF alpha: 86-150/233.


Purification: affinity purified by Protein A

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.


Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, psoriasis, rheumatoid arthritis ankylosing spondylitis, tuberculosis, autosomal dominant polycystic kidney disease, and cancer. Mutations in this gene affect susceptibility to cerebral malaria, septic shock, and Alzheimer disease. Knockout studies in mice also suggested the neuroprotective function of this cytokine. [provided by RefSeq, Aug 2020]


VALIDATION IMAGES




Sample: Lane 1: A431 (Human) Cell Lysate at 30 ug Lane 2: A431 (Human) Cell Lysate at 30 ug Primary: Anti-TNF alpha (bs-0078R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 26/17 kD Observed band size: 26 kD



Blank control:THP-1. Primary Antibody (green line): Rabbit Anti-TNF alpha antibody (bs-0078R) Dilution: 1ug/Test; Secondary Antibody : Goat anti-rabbit IgG-FITC Dilution: 0.5ug/Test. Protocol The cells were treated with TPA (80 nM, overnight) and then treated with LPS (1 ug/mL, 18 hr/6 hr) and Brefeldin A (300 ng/mL, last 3 hr of stimulation) .The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 0.1% PBST for 20 min at room temperature.The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.



Blank control:Raw264.7. Primary Antibody (green line): Rabbit Anti-TNF alpha antibody (bs-0078R) Dilution: 2ug/Test; Secondary Antibody : Goat anti-rabbit IgG-FITC Dilution: 0.5ug/Test. Protocol The cells were treated with LPS (1 ug/mL, 18 hr/6 hr) and Brefeldin A (300 ng/mL, last 3 hr of stimulation).The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 0.1% PBST for 20 min at room temperature.The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.



Blank control:Raw264.7. Primary Antibody (green line): Rabbit Anti-TNF alpha antibody (bs-0078R) Dilution: 2ug/Test; Secondary Antibody : Goat anti-rabbit IgG-FITC Dilution: 0.5ug/Test. Protocol The cells were treated with LPS (1 ug/mL, 18 hr/6 hr) and Brefeldin A (300 ng/mL, last 3 hr of stimulation).The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 0.1% PBST for 20 min at room temperature.The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

PRODUCT SPECIFIC PUBLICATIONS

[IF=13.273] Xuefang Hao. et al. Biomimetic and responsive nanoparticles loading JQ1 for dual-targeting treatment of vascular restenosis via multiple actions. Chem Eng J. 2021 Nov;;133452 WB ; Mouse . 10.1016/j.cej.2021.133452

[IF=13.273] Fangyu Qiao. et al. 4-Octyl itaconate modified demineralized bone matrix scaffold improves bone repair by regulating early inflammation. Chem Eng J. 2021 Dec;425:131490 WB,IF ; Rat . 10.1016/j.cej.2021.131490

[IF=11.092] Fangyu Qiao. et al. Hybrid Cell Membrane-Functionalized Matrixes for Modulating Inflammatory Microenvironment and Improving Bone Defect Repair. ADV HEALTHC MATER. 2023 Apr;;2203047 IF ; Rat . 37059691

[IF=8.579] Siqi Ying. et al. Low-intensity Pulsed Ultrasound regulates alveolar bone homeostasis in experimental Periodontitis by diminishing Oxidative Stress. Theranostics. 2020; 10(21): 9789–9807 IHC ; Mouse, Rat . 32863960

[IF=8.34] Liu et al. Autophagy induced by DAMPs facilitates the inflammation response in lungs undergoing ischemia-reperfusion injury through promoting TRAF6 ubiquitination. (2017) Cell.Death.Diffe. 24:683-693 IHC,WB ; Porcine . 28157209